Astec Lifesciences Key Ratios
NSE: ASTEC | BSE: 533138
₹649.60
As on 28-Oct-2026 12:44IST
Market cap
₹1,446 Cr
Revenue (TTM)
₹439 Cr
P/E Ratio
--
P/B Ratio
4.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -13.81 | -2.31 | 16.06 | -4.11 | -3.30 |
| EBIT | -163.97 | -80.86 | 16.32 | -198.00 | -193.94 |
| Net Profit | -99.85 | -53.14 | 32.00 | -200.24 | -207.86 |
| EPS | -99.85 | -53.13 | 36.54 | -190.35 | -205.83 |
| Book Value | -- | -- | 47.54 | -6.17 | 2.29 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| -16.37 | -4.92 | -11.97 | -11.03 | -28.83 |
| Net Margin
| -20.95 | -9.14 | -17.93 | -17.84 | -34.82 |
| Return on equity
| -27.56 | -10.13 | -21.36 | -25.88 | -44.64 |
| Return on Capital
| -7.63 | 1.43 | -- | -5.71 | -12.62 |
| Return on Assets
| -9.39 | -2.84 | -9.48 | -8.84 | -14.47 |
| Debt to Equity (x)
| -- | -- | 0.09 | 1.15 | 2.36 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
-5.71
|
-12.62
|
-4.50
|
7.75
|
|
Peer Median
|
--
|
16.22
|
12.22
|
21.63
|
--
|
ROE
-21.36
Lower than Peers by 32.91
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
-21.36
|
-25.88
|
-44.64
|
-11.90
|
6.28
|
|
Peer Median
|
11.55
|
12.46
|
9.23
|
18.08
|
--
|
ROA
-9.48
Lower than Peers by 16.75
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
-9.48
|
-8.84
|
-14.47
|
-4.80
|
2.69
|
|
Peer Median
|
7.27
|
7.01
|
5.98
|
9.92
|
--
|
EBIT Margin
-11.97
Lower than Peers by 20.71
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
-11.97
|
-11.03
|
-28.83
|
-9.20
|
6.78
|
|
Peer Median
|
8.73
|
10.14
|
9.68
|
7.64
|
--
|
Net Margin
-17.93
Lower than Peers by 24.82
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
-17.93
|
-17.84
|
-34.82
|
-10.11
|
3.99
|
|
Peer Median
|
6.90
|
6.37
|
5.63
|
8.97
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
-8.02
|
-23.37
|
-2.32
|
9.39
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
16.06
Higher than Peers by 9.21
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
16.06
|
17.53
|
-16.78
|
-27.06
|
-7.15
|
|
Peer Median
|
6.85
|
8.30
|
7.71
|
-11.85
|
--
|
EBIT Growth
16.32
Higher than Peers by 2.34
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
16.32
|
55.02
|
-160.69
|
-198.98
|
-64.41
|
|
Peer Median
|
13.99
|
17.10
|
31.57
|
-36.92
|
--
|
Net Profit Growth
32.00
Higher than Peers by 17.72
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
32.00
|
39.96
|
-187.29
|
-283.21
|
-71.53
|
|
Peer Median
|
14.28
|
19.26
|
30.59
|
-41.41
|
--
|
EPS Growth
36.54
Higher than Peers by 25.07
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
36.54
|
46.76
|
-187.11
|
-283.54
|
-71.56
|
|
Peer Median
|
11.47
|
30.16
|
31.07
|
-42.07
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
66.42
|
-36.40
|
-11.96
|
5.76
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.09
Higher than Peers by 0.08
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
0.09
|
1.15
|
2.36
|
1.34
|
0.81
|
|
Peer Median
|
0.00
|
0.11
|
0.05
|
0.11
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
0.79
|
1.13
|
0.77
|
0.68
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.74
Lower than Peers by 1.21
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
0.74
|
0.89
|
0.93
|
1.00
|
0.95
|
|
Peer Median
|
1.95
|
1.79
|
2.07
|
1.63
|
--
|
Quick Ratio
0.34
Lower than Peers by 0.94
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
0.34
|
0.61
|
0.50
|
0.51
|
0.39
|
|
Peer Median
|
1.28
|
1.13
|
1.23
|
1.13
|
--
|
Interest Coverage
-1.67
Lower than Peers by 21.16
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
-1.67
|
-1.35
|
-2.84
|
-1.45
|
2.69
|
|
Peer Median
|
19.49
|
17.49
|
12.22
|
12.03
|
--
|
Operating Efficiency
Debtors to sales
24.59
Lower than Peers by 6.89
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
24.59
|
55.28
|
38.67
|
36.89
|
24.66
|
|
Peer Median
|
31.47
|
28.84
|
30.54
|
25.72
|
--
|
Asset Turnover
0.52
Lower than Peers by 0.33
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
0.52
|
0.49
|
0.42
|
0.47
|
0.66
|
|
Peer Median
|
0.85
|
0.86
|
0.85
|
0.88
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
160.92
|
148.32
|
128.71
|
123.89
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
121.29
|
166.70
|
194.99
|
139.30
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
103.52
|
105.03
|
152.31
|
166.93
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
178.69
|
209.98
|
171.39
|
96.26
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-18.49
Lower than Peers by 39.95
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
-18.49
|
--
|
--
|
--
|
106.02
|
|
Peer Median
|
21.45
|
19.40
|
39.81
|
50.05
|
--
|
Price / Book Value
4.32
Higher than Peers by 1.98
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
4.32
|
3.08
|
5.64
|
5.65
|
6.47
|
|
Peer Median
|
2.34
|
2.47
|
4.60
|
3.48
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
--
|
--
|
--
|
0.11
|
|
Peer Median
|
0.36
|
0.34
|
0.20
|
0.55
|
--
|
EV/EBITDA
-704.77
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
-704.77
|
3,007.12
|
-30.96
|
-9,579.67
|
34.14
|
|
Peer Median
|
--
|
13.83
|
29.16
|
19.72
|
--
|
Market Cap
1,446
Lower than Peers by 1,172
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
1,446
|
1,202
|
1,323
|
2,083
|
2,710
|
|
Peer Median
|
2,619
|
2,088
|
4,155
|
3,052
|
--
|